192 related articles for article (PubMed ID: 19772879)
1. Multifunctional role of VIP in prostate cancer progression in a xenograft model: suppression by curcumin and COX-2 inhibitor NS-398.
Fernández-Martínez AB; Bajo AM; Valdehita A; Isabel Arenas M; Sánchez-Chapado M; Carmena MJ; Prieto JC
Peptides; 2009 Dec; 30(12):2357-64. PubMed ID: 19772879
[TBL] [Abstract][Full Text] [Related]
2. Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells.
Fernández-Martínez AB; Bajo AM; Sánchez-Chapado M; Prieto JC; Carmena MJ
Prostate; 2009 May; 69(7):774-86. PubMed ID: 19189304
[TBL] [Abstract][Full Text] [Related]
3. Vasoactive intestinal peptide enhances growth and angiogenesis of human experimental prostate cancer in a xenograft model.
Collado B; Carmena MJ; Clemente C; Prieto JC; Bajo AM
Peptides; 2007 Sep; 28(9):1896-901. PubMed ID: 17544169
[TBL] [Abstract][Full Text] [Related]
4. Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-kappaB in human prostate cell lines Differential time-dependent responses in cancer progression.
Fernández-Martínez AB; Collado B; Bajo AM; Sánchez-Chapado M; Prieto JC; Carmena MJ
Mol Cell Endocrinol; 2007 May; 270(1-2):8-16. PubMed ID: 17434257
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo.
Dorai T; Cao YC; Dorai B; Buttyan R; Katz AE
Prostate; 2001 Jun; 47(4):293-303. PubMed ID: 11398177
[TBL] [Abstract][Full Text] [Related]
6. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer.
Wang L; Chen W; Xie X; He Y; Bai X
Exp Oncol; 2008 Mar; 30(1):42-51. PubMed ID: 18438340
[TBL] [Abstract][Full Text] [Related]
7. NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model.
Nishikawa M; Stapleton PP; Freeman TA; Gaughan JP; Matsuda T; Daly JM
J Am Coll Surg; 2004 Sep; 199(3):428-35. PubMed ID: 15325613
[TBL] [Abstract][Full Text] [Related]
8. The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo.
Hong JH; Ahn KS; Bae E; Jeon SS; Choi HY
Prostate Cancer Prostatic Dis; 2006; 9(2):147-52. PubMed ID: 16389264
[TBL] [Abstract][Full Text] [Related]
9. Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone.
Sotomayor S; Carmena MJ; Schally AV; Varga JL; Sánchez-Chapado M; Prieto JC; Bajo AM
Int J Oncol; 2007 Nov; 31(5):1223-30. PubMed ID: 17912451
[TBL] [Abstract][Full Text] [Related]
10. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice.
Aggarwal BB; Shishodia S; Takada Y; Banerjee S; Newman RA; Bueso-Ramos CE; Price JE
Clin Cancer Res; 2005 Oct; 11(20):7490-8. PubMed ID: 16243823
[TBL] [Abstract][Full Text] [Related]
11. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2.
Pyo H; Choy H; Amorino GP; Kim JS; Cao Q; Hercules SK; DuBois RN
Clin Cancer Res; 2001 Oct; 7(10):2998-3005. PubMed ID: 11595687
[TBL] [Abstract][Full Text] [Related]
12. Prolonging androgen sensitivity in prostate cancer - a role for COX inhibitors?
Richards A; McGeechan K; Niknam M; Salomon R; Kurek C; Dong Q; Patel MI
ANZ J Surg; 2009 Sep; 79(9):641-7. PubMed ID: 19895521
[TBL] [Abstract][Full Text] [Related]
13. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo.
Adhami VM; Malik A; Zaman N; Sarfaraz S; Siddiqui IA; Syed DN; Afaq F; Pasha FS; Saleem M; Mukhtar H
Clin Cancer Res; 2007 Mar; 13(5):1611-9. PubMed ID: 17332308
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase-2 promotes prostate cancer progression.
Fujita H; Koshida K; Keller ET; Takahashi Y; Yoshimito T; Namiki M; Mizokami A
Prostate; 2002 Nov; 53(3):232-40. PubMed ID: 12386924
[TBL] [Abstract][Full Text] [Related]
15. Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice.
Khor TO; Keum YS; Lin W; Kim JH; Hu R; Shen G; Xu C; Gopalakrishnan A; Reddy B; Zheng X; Conney AH; Kong AN
Cancer Res; 2006 Jan; 66(2):613-21. PubMed ID: 16423986
[TBL] [Abstract][Full Text] [Related]
16. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
[TBL] [Abstract][Full Text] [Related]
17. [Inhibitory effects of cyclooxygenase-2 inhibitor celecoxib on growth and angiogenesis of human liver cancer HepG2 cell xenografts in small nude mice].
Zuo CH; Li ZR; Zhou X; Ouyang YZ; Zhou ZY; Zeng L
Ai Zheng; 2006 Apr; 25(4):414-20. PubMed ID: 16613672
[TBL] [Abstract][Full Text] [Related]
18. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.
Zhang Y; Ma Y; Lu HP; Gao JH; Liang CS; Liu CZ; Zou JT; Wang HQ
Chin Med J (Engl); 2008 Nov; 121(22):2284-9. PubMed ID: 19080333
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.
Plonowski A; Schally AV; Letsch M; Krupa M; Hebert F; Busto R; Groot K; Varga JL
Prostate; 2002 Aug; 52(3):173-82. PubMed ID: 12111694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]